Protagonist Therapeutics
(NASDAQ) PTGX
Protagonist Therapeutics Financials at a Glance
Market Cap
$6.32B
Revenue (TTM)
$46.02M
Net Income (TTM)
$130.15M
EPS (TTM)
$-2.04
P/E Ratio
-48.45
Dividend
$0.00
Beta (Volatility)
1.28 (Average)
Dividend
$0.00
Beta (Volatility)
1.28 (Average)
Price
$99.22
Volume
25,023
Open
$102.02
Price
$99.22
Volume
25,023
Open
$102.02
Previous Close
$99.22
Daily Range
$97.86 - $102.02
52-Week Range
$39.60 - $105.69
Dividend
$0.00
Beta (Volatility)
1.28 (Average)
Price
$99.22
Volume
25,023
Open
$102.02
Previous Close
$99.22
Daily Range
$97.86 - $102.02
52-Week Range
$39.60 - $105.69
PTGX News
PTGX: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Protagonist Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
132
CEO
Dinesh V. Patel, PhD
Website
www.protagonist-inc.comHeadquarters
Newark, CA 94560-1160, US
PTGX Financials
Key Financial Metrics (TTM)
Gross Margin
99%
Operating Margin
-3%
Net Income Margin
-3%
Return on Equity
-20%
Return on Capital
-25%
Return on Assets
-19%
Earnings Yield
-2.06%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$6.32B
Shares Outstanding
63.81M
Volume
25.02K
Short Interest
0.00%
Avg. Volume
801.09K
Financials (TTM)
Gross Profit
$44.79M
Operating Income
$158.13M
EBITDA
$128.09M
Operating Cash Flow
$57.67M
Capital Expenditure
$1.59M
Free Cash Flow
$56.08M
Cash & ST Invst.
$567.36M
Total Debt
$10.32M
Protagonist Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$7.44M
-95.6%
Gross Profit
$7.06M
-95.9%
Gross Margin
94.94%
N/A
Market Cap
$6.32B
N/A
Market Cap/Employee
$50.93M
N/A
Employees
124
N/A
Net Income
$44.38M
-133.7%
EBITDA
$43.34M
-134.0%
Quarterly Fundamentals
Net Cash
$557.04M
+36.5%
Accounts Receivable
$4.50M
-97.3%
Inventory
$0.00
N/A
Long Term Debt
$8.04M
-22.4%
Short Term Debt
$2.28M
+347.6%
Return on Assets
-19.43%
N/A
Return on Invested Capital
-25.32%
N/A
Free Cash Flow
$35.53M
-20.5%
Operating Cash Flow
$36.98M
-26.7%